Viyash Scientific Limited · NSE:VIYASH

Viyash Scientific — Investor Day (June 2026)

50 slides from Viyash Scientific's investor day presentation, Jun 25, 2026

Slide 1: Submission of Investor Day presentation (exchange cover letter)
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000 E: investorrelations@viyash.com W
Slide 3: Agenda
Agenda Section 01 Welcome Section 02 Our journey Section 03 Our strengths Section 04 Business snapshot Section 05 Growth drivers Section 06 Our aspiration © 2026 Viyash Scientific Ltd. All Rights Reserved. 2
Slide 5: About our MD & CEO
About our MD & CEO Dr. Haribabu Bodepudi is the MD & Group CEO of Viyash Scientific Limited since Dec 2025 Dr. Hari has 30 years of extensive experience in the pharmaceutical industry, prior to being appointed as the Group CEO, Dr. Hari was the CEO of Viyash Life Sciences, which he promoted alongsid
Slide 7: Who we are?
Who we are? We are an integrated pharmaceutical platform across animal and human health backed by science and IP IP and Global presence Backward Front end Strong technology across animal integrated presence in management driven company and human capabilities key markets team with health global exper
Slide 8: Our Journey
Our Journey Viyash Life Sciences Foundation & Early Growth Scale & Expansion Integration & Global Reach Founded in February 2019 by Acquisition of Mylan's API and Unified manufacturing operations, Dr Haribabu Bodepudi. formulation units in Vizag and Mumbai. expanded R&D to over 200 scientists, filed
Slide 9: Both businesses have had their own individual strengths
Both businesses have had their own individual strengths Sequent Scientific Limited Viyash Life Sciences Strong frontend Only USFDA Strong Backward integrated presence in large approved API manufacturing to intermediates animal health markets facility for animal and R&D setup providing cost - Europe,
Slide 11: Management Team
Management Team Ramakant Singani AVV Srinivas (Group CFO) (SVP – R&D Head) Rajaram Narayanan Rajkamal Varshney (CEO – Animal Health) (SVP – Head of BD) Dr AJ Reddy (SVP – Head of SCM) Alexis Goux BN Srinivas (COO – Animal Health) (Regulatory and Quality) Yoshita Vora (Company Secretary) Dr. Peddanna
Slide 12: 16 world class manufacturing facilities
16 world class manufacturing facilities Turkey USA Spain 10 API MANUFACTURING Brazil I SITES India – AH Formulations Brazil II API Formulations © 2026 Viyash Scientific Ltd. All Rights Reserved. 11
Slide 13: API manufacturing capabilities
API manufacturing capabilities Site Capabilities Regulatory Approvals USFDA/ EU-GMP/ PMDA/ TGA/ Viyash Scientific Unit I (Viyash -1) API / HP API KFDA/ WHO-GMP USFDA/ EU-GMP/ Viyash Scientific Unit II (Viyash -2) API/ HP API WHO-GMP/ANVISA USFDA/ EU-GMP/ WHO-GMP / Viyash Scientific Unit III (Symed -
Slide 14: Formulations manufacturing sites
Formulations manufacturing sites Site Type of formulation Regulatory Approvals Turkey Animal EU GMP/ Turkish GMP Brazil Unit I Animal Brazil GMP Brazil Unit II Animal Brazil GMP India Animal WHO-Geneva Spain Animal EU GMP/ Turkish GMP USA Human USFDA © 2026 Viyash Scientific Ltd. All Rights Reserved
Slide 15: Formulations manufacturing capabilities
Formulations manufacturing capabilities Manufacturing capabilities Dosage Form Spain Turkey Brazil India US (HH) Oral Liquid Oral Solution Liquid for inhalation Oral Suspension Water Soluble Powder Drug Premix Nutritional Feed Add. Injectable Inj. Solution Inj. Suspension Pre-Filled Syringes Granule
Slide 16: Our R&D landscape
Our R&D landscape Turkey Spain India • Animal Formulations • Human Formulations • API Brazil R&D centre Location Capabilities / dosage forms Technologies & infrastructure R&D members • Scalable complex APIs incl. high-potent • 20+ chemical R&D labs; dedicated process- India (Hyderabad, API R&D (OEB
Slide 17: R&D capabilities - Formulations
R&D capabilities - Formulations Dosage Form Spain Turkey Brazil India (AH) India (HH) Oral Liquid Oral Solution Liquid for inhalation Oral Suspension Water Soluble Powder Drug Premix Nutritional Feed Add. Injectable Inj. Solution Inj. Suspension Pre-Filled Syringes Granules for Injection Gases Aeros
Slide 18: R&D capabilities - API
R&D capabilities - API High potent reactions Best in class analytical center Process safety lab Complex molecules like Iron complex Human API Animal API Delivering 60 PATENTS FILED since FY23 with 57 regulatory 16 REGULATORY Results approvals and 14 patents granted; 185+ patents filings since FY23 w
Slide 19: Animal formulations portfolio
Animal formulations portfolio Companion Animals Commercial Under development / Pipeline Number of Products 10+ 66+ Global Market Size ($MN) NA ~15,400 Farm Animals Commercial Under development / Pipeline Number of Products 130+ 21+ Global Market Size ($MN) NA ~1,000 © 2026 Viyash Scientific Ltd. All
Slide 20: API portfolio
API portfolio Animal API Commercial Under development / Pipeline Number of Products 33 24 (2 first to file launches) Total Addressable Market Size ($MN) NA ~1,600 Human API Commercial Under development / Pipeline Number of Products 60 63 (22 first to file launches) Total Addressable Market Size ($MN
Slide 21: Human formulations portfolio
Human formulations portfolio Commercial Under development / Pipeline Number of Molecules 30+ 24 (11 first to file launches) Total Addressable Market Size ($MN) NA ~6,200 © 2026 Viyash Scientific Ltd. All Rights Reserved. Source: market size basis publicly available data and assumptions on API cost a
Slide 23: Presence across 150+ countries
Presence across 150+ countries Key European markets, US, Europe, India, Human Animal emerging markets US Emerging markets API formulations including LATAM and India and others formulations © 2026 Viyash Scientific Ltd. All Rights Reserved. 22
Slide 25: An integrated pharmaceutical platform
An integrated pharmaceutical platform From two individual growth engines to one powerhouse platform Revenue (INR MN) EBITDA (INR MN) 34,203 7,025 30,068 4,400 26,807 2,739 FY24 FY25 FY26 FY24 FY25 FY26 © 2026 Viyash Scientific Ltd. All Rights Reserved. 24
Slide 26: Strong momentum post merger
Strong momentum post merger Revenue (INR MN) EBITDA (INR MN) % yoy growth 9,200 1,883 2,001 8,503 8,584 1,854 7,916 1,287 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY26 Q2FY26 Q3FY26 Q4FY26 9% 16% 11% 19% 26% 82% 65% 64% What did we do to achieve this? Product and cost Network synergies- Corporate and optimizat
Slide 28: We are seeing multiple synergies as a result of the combination
We are seeing multiple synergies as a result of the combination Corporate G&A R&D integration Procurement All corporate and API R&D has been Combined support functions fully integrated procurement initiated integrated successfully Product & capacity optimization Capacity optimization Revenue Synergi
Slide 31: Combined platform has global scale needed to capture mega trends
Combined platform has global scale needed to capture mega trends in market Market opportunity What it takes to win? Combined platform strength • Market access Companion Animals • R&D capabilities Increasing pet ownership and genericization • Backward integration Yes • Manufacturing efficiency and se
Slide 32: Growth drivers
Growth drivers Companion New product development, Market expansion, Manufacturing Animals expansion and M&A Animal formulations Farm Animals Portfolio completion, Geo extension Portfolio expansion, Day 1 launch, complex CDMO API & CDMO API integrated play, complex products including oncology Human f
Slide 34: Companion animal market is accelerating towards genericization
Market Opportunity Companion animal market is accelerating towards genericization $22Bn $32Bn TODAY 2030 10.8 14% Generics Branded 6.0 Market size ($bn) 28% 4.2 86% 50% 72% 1.2 50% 25% 0.4 75% 75% 25% USA Europe APAC LATAM Others © 2026 Viyash Scientific Ltd. All Rights Reserved. Source: market size
Slide 35: Increasing pet ownership
Market Opportunity Increasing pet ownership 1.4bn 46% 66% Dogs and cats are kept as Of EU house Of US households pets world-wide holds own a pet own a pet © 2026 Viyash Scientific Ltd. All Rights Reserved. Source: public sources 34
Slide 36: Our Focus Markets
Our Focus Markets Market Viyash Present? Companion animal market size ($bn) UK No 1.1 France No 0.9 Germany No 0.8 Italy Yes 0.8 Australia No 0.6 Phase 1 Canada No 0.6 Brazil Yes 0.5 Spain Yes 0.4 Benelux Yes 0.2 Mexico Yes 0.2 Rest of Europe Yes 1.1 India Yes 0.2 Phase 2 US No 10.3 © 2026 Viyash Sc
Slide 37: Product Opportunity
Product Opportunity Market size ($bn) Addressable market of Therapy Area [non -US] our pipeline ($bn) Parasiticides 5.4 4.9 Dermatology 1.1 0.5 Large addressable market -> we are Pain management 1.1 0.9 investing in R&D, manufacturing Cardiology 0.4 0.3 and market access Anti -infectives 0.8 0.6 Oth
Slide 38: Bio For Life acquisition in Italy
Bio For Life acquisition in Italy We have signed an acquisition in Italy aligned with our strategy Companion animal Provides access to a portfolio (85 -90 01 large companion 02 products) that can be animal market in Italy extended to other core markets Launch our global pipeline in Italy; Strong tal
Slide 39: Our aspiration
Our aspiration Target by 2032 150-200Mn Become a top 10 animal $ health player globally Revenue From companion animals © 2026 Viyash Scientific Ltd. All Rights Reserved. 38 © 2026 Viyash Scientific Ltd. All Rights Reserved.
Slide 41: Key drivers
Key drivers Geo Extension Strong and proven 25+ products to product portfolio which be geo extended we are registering across all core markets New products Diverse product 20+ new products portfolio; continuous added in pipeline focus to bridge gaps New markets Enter new, large markets Vietnam, Aust
Slide 43: Lifecycle management CDMO: Innovator business
Lifecycle management CDMO: Innovator business Our strengths Fully Quality Cost Impeccably Integrated focused Efficient compliant 15 $ 2.5Bn Products Total market size of existing and pipeline products Targeting 20%+ growth in the segment © 2026 Viyash Scientific Ltd. All Rights Reserved. Source: mar
Slide 44: API & CDMO: Specialty and Generics business
API & CDMO: Specialty and Generics business Partnership models Contract Co -investment R&D and manufacturing manufacturing 15 28 9 $ 80Bn Partners Projects First to file Market size of projects all projects Target to triple (>25%+ CAGR) the business over next 5 years © 2026 Viyash Scientific Ltd. Al
Slide 46: Human formulations
Human formulations Growth levers Patent Integrated Large oral solids and cliffs oncology play liquids market 60+ 28 $ 4.5Bn Products New products Market size of products © 2026 Viyash Scientific Ltd. All Rights Reserved. Source: market size data basis public sources 45
Slide 49: Disclaimer
Disclaimer • This document has been prepared by Viyash Scientific Limited (“Company”) and contains certain statements that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws. All statements that are not statements of historical fact, including statement

Viyash Scientific — Investor Day (June 2026) on 6ix

Viyash Scientific — Investor Day (June 2026)

Slide 1: Submission of Investor Day presentation (exchange cover letter)

Slide 2: Viyash Scientific Investor Day

Slide 3: Agenda

Slide 4: Welcome

Slide 5: About our MD & CEO

Slide 6: Our Journey and Mission

Slide 7: Who we are?

Slide 8: Our Journey

Slide 9: Both businesses have had their own individual strengths

Slide 10: Strengths of the Combination

Slide 11: Management Team

Slide 12: 16 world class manufacturing facilities

Slide 13: API manufacturing capabilities

Slide 14: Formulations manufacturing sites

Slide 15: Formulations manufacturing capabilities

Slide 16: Our R&D landscape

Slide 17: R&D capabilities - Formulations

Slide 18: R&D capabilities - API

Slide 19: Animal formulations portfolio

Slide 20: API portfolio

Slide 21: Human formulations portfolio

Slide 22: Business Snapshot

Slide 23: Presence across 150+ countries

Slide 24: Key partnerships

Slide 25: An integrated pharmaceutical platform

Slide 26: Strong momentum post merger

Slide 27: Synergies

Slide 28: We are seeing multiple synergies as a result of the combination

Slide 29: Growth Drivers

Slide 30: Our business segments

Slide 31: Combined platform has global scale needed to capture mega trends

Slide 32: Growth drivers

Slide 33: Animal Formulations (Companion Animals)

Slide 34: Companion animal market is accelerating towards genericization

Slide 35: Increasing pet ownership

Slide 36: Our Focus Markets

Slide 37: Product Opportunity

Slide 38: Bio For Life acquisition in Italy

Slide 39: Our aspiration

Slide 40: Animal Formulations (Farm Animals)

Slide 41: Key drivers

Slide 42: API + CDMO

Slide 43: Lifecycle management CDMO: Innovator business

Slide 44: API & CDMO: Specialty and Generics business

Slide 45: Human Formulations

Slide 46: Human formulations

Slide 47: Our Aspirations

Slide 48: Our 2032 Aspirations

Slide 49: Disclaimer

Slide 50: Thank You